Biogen IDEC (BIIB) and partner Swedish Orphan Biovitrum (BIOVF.PK) see positive top-line results...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen IDEC (BIIB) and partner Swedish Orphan Biovitrum (BIOVF.PK) see positive top-line results from a study of their clotting factor candidate for patients with hemophilia B. The recombinant Factor IX Fc fusion protein was "generally well tolerated" and offers a more long-lasting treatment than current therapies requiring up to three intravenous injections a week. BIIB +2.4% premarket.